Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future medical prospects for Sandostatin.

A G Harris1

  • 1Dept. Neuroendocrinology, SANDOZ Ltd., Basle, Switzerland.

Zeitschrift Fur Gastroenterologie
|September 1, 1990
PubMed
Summary

Sandostatin, a long-acting somatostatin analogue, effectively treats various tumors and gastrointestinal disorders. Its applications extend to cancer therapy, diagnostic imaging, and other conditions, with ongoing clinical trials exploring its full potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Creating new guidelines on how best to treat foot symptoms in people with EB.

The British journal of dermatology·2020
Same author

Foot care in epidermolysis bullosa: evidence-based guideline.

The British journal of dermatology·2019
Same author

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone·2018
Same author

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area.

International journal of women's dermatology·2017
Same author

The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Oncology

Background:

  • Native somatostatin has broad inhibitory actions but limited clinical use due to its short duration.
  • Sandostatin, a synthetic analogue, overcomes these limitations with prolonged action.
  • Somatostatin receptors are present in various tissues, including pituitary and GEP tumors.

Purpose of the Study:

  • To review the therapeutic applications of Sandostatin.
  • To highlight its efficacy in treating pituitary and GEP endocrine tumors.
  • To explore its potential as an adjunctive cancer therapy and in other medical conditions.

Main Methods:

  • Review of preclinical and clinical studies on Sandostatin.
  • Analysis of Sandostatin's effects on hormone secretion, tumor growth, and gastrointestinal functions.
  • Evaluation of diagnostic and therapeutic applications of radiolabeled somatostatin analogues.

Main Results:

  • Sandostatin is effective in treating GH/TSH-secreting pituitary tumors and GEP endocrine tumors.
  • Preclinical studies show antineoplastic activity; potential as adjunctive cancer therapy is being investigated.
  • Positive results reported for esophageal variceal bleeding, pancreatic conditions, short bowel syndrome, and refractory diarrhea.
  • Preliminary efficacy noted in psoriasis, autonomic neuropathy, and reducing height velocity.

Conclusions:

  • Sandostatin is a valuable therapeutic agent for various endocrine and gastrointestinal disorders.
  • Its role in oncology, diagnostics, and other conditions warrants further investigation.
  • Ongoing clinical trials are crucial to define its ultimate therapeutic role.

Related Experiment Videos